[go: up one dir, main page]

WO2007038868A3 - Nouveau compose d'enediyne et ses utilisations - Google Patents

Nouveau compose d'enediyne et ses utilisations Download PDF

Info

Publication number
WO2007038868A3
WO2007038868A3 PCT/CA2006/001634 CA2006001634W WO2007038868A3 WO 2007038868 A3 WO2007038868 A3 WO 2007038868A3 CA 2006001634 W CA2006001634 W CA 2006001634W WO 2007038868 A3 WO2007038868 A3 WO 2007038868A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
uncialamycin
methods
compound
kill
Prior art date
Application number
PCT/CA2006/001634
Other languages
English (en)
Other versions
WO2007038868A2 (fr
Inventor
Julian E Davies
Raymond J Anderson
Hao Wang
Koaru Warabi
Xin Hui Huang
Original Assignee
Univ British Columbia
Julian E Davies
Raymond J Anderson
Hao Wang
Koaru Warabi
Xin Hui Huang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia, Julian E Davies, Raymond J Anderson, Hao Wang, Koaru Warabi, Xin Hui Huang filed Critical Univ British Columbia
Publication of WO2007038868A2 publication Critical patent/WO2007038868A2/fr
Publication of WO2007038868A3 publication Critical patent/WO2007038868A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne un nouveau composé d'énédiyne, l'uncialamycine, et ses analogues. Elle concerne également des méthodes d'utilisation du composé pour traiter des infections bactériennes, inhiber la croissance bactérienne, et tuer des bactéries. Le composé de l'invention peut également être utilisé pour traiter des tumeurs, empêcher la croissance de cellules tumorales, tuer des cellules tumorales, traiter des cancers, empêcher la croissance de cellules cancéreuses, et tuer des cellules cancéreuses. L'invention concerne aussi des méthodes de production d'analogues d'uncialamycine. Elle concerne en outre des compositions comprenant l'uncialamycine et des méthodes d'administration des compositions de l'invention.
PCT/CA2006/001634 2005-10-03 2006-10-03 Nouveau compose d'enediyne et ses utilisations WO2007038868A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72240705P 2005-10-03 2005-10-03
US60/722,407 2005-10-03

Publications (2)

Publication Number Publication Date
WO2007038868A2 WO2007038868A2 (fr) 2007-04-12
WO2007038868A3 true WO2007038868A3 (fr) 2007-11-08

Family

ID=37906518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2006/001634 WO2007038868A2 (fr) 2005-10-03 2006-10-03 Nouveau compose d'enediyne et ses utilisations

Country Status (1)

Country Link
WO (1) WO2007038868A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700137T1 (it) * 2012-02-13 2017-05-08 Bristol Myers Squibb Co Composti di endiini, loro coniugati, e loro usi e metodi
CN105899515B (zh) * 2013-08-14 2020-01-14 威廉马歇莱思大学 uncialamycin的衍生物、合成方法及其作为抗肿瘤剂的用途
SG11201607818WA (en) 2014-03-20 2016-10-28 Bristol Myers Squibb Co Stabilized fibronectin based scaffold molecules
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
US10653791B2 (en) 2014-11-21 2020-05-19 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
ES2822990T3 (es) 2014-11-25 2021-05-05 Bristol Myers Squibb Co Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes
US10336766B2 (en) * 2015-01-08 2019-07-02 The Scripps Research Institute Anticancer drug candidates
US10676773B2 (en) 2015-03-10 2020-06-09 Bristol-Myers Squibb Company Antibodies conjugatable by transglutaminase and conjugates made therefrom
ES2936317T3 (es) 2015-05-29 2023-03-16 Bristol Myers Squibb Co Anticuerpos contra OX40 y usos de los mismos
CA2998740A1 (fr) * 2015-09-17 2017-03-23 The Scripps Research Institute Immunoconjugues a double domaine variable et leurs utilisations
ES2809125T3 (es) 2015-09-23 2021-03-03 Bristol Myers Squibb Co Moléculas de armazón a base de fibronectina de unión a glipicano-3
JP2019505575A (ja) 2015-12-21 2019-02-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 部位特異的な結合のための変異型抗体
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
WO2018048975A1 (fr) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Utilisation d'un anticorps anti-pd-1 en combinaison avec un anticorps anti-mésothéline dans le traitement du cancer
EP3630833A1 (fr) 2017-05-25 2020-04-08 Bristol-Myers Squibb Company Anticorps comprenant des régions constantes de chaîne lourde modifiées
KR20210096167A (ko) 2018-11-28 2021-08-04 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
HRP20230500T1 (hr) 2018-11-30 2023-07-21 Bristol-Myers Squibb Company Antitijelo koje sadrži c-terminalnu ekstenziju lakog lanca koja sadrži glutamin, njegovi konjugati, i postupci i primjene
WO2020123425A2 (fr) 2018-12-12 2020-06-18 Bristol-Myers Squibb Company Anticorps modifiés pour la conjugaison de la transglutaminase, conjugués associés, et méthodes et utilisations
WO2021055306A1 (fr) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Méthode de capture double d'analyse de conjugués anticorps-médicament
CN116813627B (zh) * 2023-06-15 2025-08-12 哈药慈航制药股份有限公司 一种天赐霉素类似物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849750A (en) * 1994-07-27 1998-12-15 California Institute Of Technology Dynemicin analogs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849750A (en) * 1994-07-27 1998-12-15 California Institute Of Technology Dynemicin analogs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVIES ET AL.: "UNCIALAMYCIN, A NEW ENEDIYNE ANTIBIOTIC", ORGANIC LETTERS, vol. 7, no. 23, 13 October 2005 (2005-10-13), pages 5233 - 5236, XP055154051, DOI: doi:10.1021/ol052081f *

Also Published As

Publication number Publication date
WO2007038868A2 (fr) 2007-04-12

Similar Documents

Publication Publication Date Title
WO2007038868A3 (fr) Nouveau compose d'enediyne et ses utilisations
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
WO2007011962A3 (fr) Traitement du cancer
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
WO2006037024A3 (fr) Sels de decitabine
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
WO2006020722A3 (fr) Compositions pharmaceutiques de beta-lapachone et d'analogues de beta-lapachone possedant un potentiel de ciblage de tumeur ameliore
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
WO2007067559A3 (fr) Agents antibacteriens
IL164509A0 (en) Furyl compounds
MX2007013624A (es) Inhibidores de proteina cinasa.
WO2006125555A3 (fr) Chinazolinones
TNSN07294A1 (en) Treatment of metastasized tumors
TW200716088A (en) Formulations and methods for treating amyloidosis
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2007076087A3 (fr) Quinazolones d'aryle substitue et leurs utilisations
WO2005037839A8 (fr) Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations.
WO2005030794A3 (fr) Derives d'hemiasterline et utilisations de ces derives
WO2008072952A3 (fr) Compositions contenant des composés anti-inflammatoires utilisées pour le traitement du cancer
WO2005085188A3 (fr) Composes et procedes pour la therapie antitumorale
WO2006089218A3 (fr) Procedes et compositions de modulation d'angiogenese
TW200720273A (en) Pharmaceutically active spiro-benzimidazoles
TW200504051A (en) Novel acridine derivatives and their use as medicaments

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06790794

Country of ref document: EP

Kind code of ref document: A2